Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03292484 · ClinicalTrials.gov registry record · Phase 3
Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)
A Phase 3 study, sponsored by Aimmune Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 911
- Enrollment target
NCT03292484: Completed Phase 3 study, sponsored by Aimmune Therapeutics.
NCT03292484 is a Phase 3 study that has completed, run by Aimmune Therapeutics. The registered enrollment target is 911 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03292484, a Phase 3 study, has completed, sponsored by Aimmune Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 911 participants
- Enrollment target
Study Summary
The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
Primary Outcome
An AE was any untoward medical occurrence in humans, whether or not considered related to the investigational product (IP), that occurred during the conduct of a clinical study. A SAE was any event that resulted in any of the following: death, life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, congenital abnormality or birth defect, or important
Interventions
- BIOLOGICAL AR101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 911 participants |
| Start Date | 2017-11-02 |
| Est. Completion | 2023-04-27 |
| Phase | Phase 3 |
What the finished NCT03292484 record still lists
NCT03292484 is an interventional study that assigns participants to a tested intervention. The registered 911 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (18% higher).
The record links to 0 conditions, and to 1 intervention - of which AR101 is the first listed.
NCT03292484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03292484 about?
NCT03292484 is a clinical study titled "Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)". The purpose of this study is to assess AR101's safety, tolerability and efficacy over an extended dosing period.
What is the current status of trial NCT03292484?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 911 participants. The study started on 2017-11-02. Estimated completion is 2023-04-27.
What interventions are being tested in trial NCT03292484?
The interventions under investigation include: AR101 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03292484?
This trial is sponsored by Aimmune Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03292484's enrollment target sits among peer trials
911 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06216548 · 909 participants · NA
E-PRIME For Children With Medical Complexity
- NCT06131840 · 914 participants · Phase 1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- NCT05658497 · 908 participants
Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI